Under construction – not a live service
Sign in
Taking people in SwitzerlandNo phase

Using Speech Recordings From a Phone App to Estimate Relapse Risk in Psychosis

Studies whether weekly speech recordings can help estimate relapse risk in people with psychosis.

Key facts

Who runs it
Philipp Homan
Where
Geneva and Zurich, SwitzerlandSee the 2 sitesAlso in 5 other countries, 5 sites
Trial code
Registry title
Speech-based Assessment of Relapse Risk in People With Psychosis
Status
Recruiting
People taking part
360 people, planned
Started
29 Jan 2026
Expected to end
31 Jan 2029
Type of study
Observational, 2 groups
Treatments tested
  • Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.
Record updated
9 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 with a psychotic disorder who are in remission, and also healthy adults as a comparison group. All take part in weekly speech recordings through a smartphone app.

Age
18 to 65 years
Sex
All sexes
Disease stage
People with psychosis: a psychotic disorder such as schizophrenia, schizoaffective disorder, schizophreniform disorder, acute psychosis, bipolar disorder with psychotic symptoms, or psychosis not otherwise specified. The first visit must be in a remission phase, with mild (3) or lower scores on three BPRS items: hallucinatory behavior, unusual thought content, conceptual disorganization.
Earlier treatment
Healthy participants should not take prescription drugs regularly. No prior treatment is asked of people with psychosis.

Main reasons for not taking part

  • Severe speech disorders (aphasia or severe stuttering) that prevent good speech recording (people with psychosis)
  • Not able or not willing to understand the purpose and details of the study
  • Any history of major diseases such as heart, nerve, metabolic, kidney, liver, lung or speech disorders (healthy participants)
  • Depression, anxiety or other psychiatric disorders, or such disorders in the family (healthy participants)
  • Recreational drug use (healthy participants)

The registry criteria, word for word

Show all 24 criteriaShow less

Other criteria

  • Healthy participants Inclusion Criteria:
  • Between 18 and 65 years old
  • Subjects must be able to provide informed consent (IC)
  • Participants must have provided signed informed consent prior to enrollment
  • Participants should not take prescription drugs regularly
  • Native or equivalent fluency in speaking and understanding one of the following languages: English, German, Dutch, French, Czech or Turkish
  • Ability to have access to a smartphone and be capable of using a mobile app for speech-based data collection
  • Must be able to comply with the study schedule and procedures; Healthy participants Exclusion Criteria:
  • Any history of major diseases (e.g., cardiovascular, neurological, metabolic, renal, hepatic, respiratory or speech disorders)
  • Recreational drug use or psychiatric disorders due to use of alcohol
  • Depression, anxiety, or other psychiatric disorders
  • Family history of depression, anxiety, or other psychiatric disorders
  • Individuals who are not able or willing to understand the purpose and details of the study; Individuals with psychosis Inclusion Criteria:
  • Between 18 and 65 years old
  • Diagnoses include psychotic disorders (schizophrenia, schizoaffective disorder, schizophreniform disorder, acute psychosis, bipolar disorder with psychotic symptoms, psychosis not otherwise specified)
  • First visit must be during remission phase (baseline measurement)
  • Current positive symptoms rated 3 (mild) or lower on all of these Brief Psychiatric Symptom Scale (BPRS) items: hallucinatory behavior, unusual thought content, conceptual disorganization
  • Must be able to comply with the study schedule and procedures
  • Subjects must be able to provide IC
  • Participants must have provided signed informed consent prior to enrollment
  • Native or equivalent fluency in speaking and understanding one of the following languages: English, German, Dutch, French, Czech or Turkish
  • Ability to have access to a smartphone and be capable of using a mobile app for speech-based data collection; Individuals with psychosis Exclusion Criteria:
  • Severe comorbid speech disorders (aphasia or severe stuttering) that prevent adequate speech recording
  • Individuals who are not able or willing to understand the purpose and details of the investigation; Citizens with psychiatric or somatic comorbidity, drug- or alcohol abuse will be allowed to participate, so that the sample will reflect the general population of citizens with psychosis and the study's endpoints will be generalizable

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in Switzerland

Also in 5 other countries, 5 sites

  • University Hospital Geneva and University of GenevaGeneva, SwitzerlandContact: Stefan Kayser, ProfNot yet recruiting
  • Psychiatric University Hospital Zurich and University of ZurichZurich, SwitzerlandContact: Giacomo Cecere, MDTaking people

About the trial

What the trial wants to find out

This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis. Over 12 months, patients at risk of relapse and healthy controls will provide weekly speech recordings and self-report data for automated analysis. Risk scores will be stored but not shared with treating clinicians. Independent clinical evaluations ensure data quality and validation. The study lays the foundation for future Clinical Decision Support System (CDSS) research and explores novel speech markers for relapse prediction while minimizing participant burden.

The 2 groups in the trial

  • At risk of relapse

    Individuals at risk of psychotic relapse

    Treatment: Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.

  • Healthy controls

    Healthy participants will be used as controls

    Treatment: Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Prospective Multicenter Study for Relapse Risk Assessment Through Language Analysis in Individuals With Psychosis
Plain-language title
Using Speech Recordings From a Phone App to Estimate Relapse Risk in PsychosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07397975, who can take part
Publications
Record updated
9 February 2026